AZN

AstraZeneca PLC

Fundamental data last updated:June 7, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - General

Exchange

NYSE

County of HQ

GB

Next Earnings Date

07/27/2026

Business Summary

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

 


Analyze AZN on TradingView

VALUATION

P/E

27.55

Market Cap ($M USD)

$288.38B

Forward P/E

11.08

PEG

0.07

PRICE TO SALES

4.71

PRICE TO BOOK

6.05

EV / EBITDA

15.24

5-Year Average P/E

Free Cash Flow Yield

3.06%

DCF Value

$560.90

Graham Number

$68.12

Price to FCF

32.63

EV to FCF

35.63

Earnings Yield

3.65%

FCF Yield

3.06%

DIVIDEND

Yield

1.70%

Annual Payout

$3.15

Payout Ratio

46.98%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$6.75

Next Year EPS Growth Estimate

$16.79

Next Year Revenue Growth Estimate

$8.23T

Return on Equity (ROE)

22.41%

FREE CASH FLOW

Operating Margin

23.53%

Debt-to-Equity

0.61

Piotroski F-Score

8

Altman Z-Score

3.58

Return on Invested Capital (ROIC)

17.57%

Current Ratio

0.91

Quick Ratio

0.71

Net Debt to EBITDA

1.28

Interest Coverage

8.54

Gross Profit margin

79.71%

FCF PER SHARE

$5.67

REVENUE PER SHARE

$39.27

Analyze AZN on TradingView

Gainseekers Quantitative Analysis

Summary

AstraZeneca’s valuation paints a compelling picture of market mispricing. With a DCF value significantly higher than recent pricing, the stock appears undervalued. The Forward P/E of 10.71 suggests growth potential, while the robust Altman Z-score of 3.63 indicates financial stability. However, the Earnings Yield of 3.75% is modest, hinting at a need for cautious optimism. Overall, the market seems to underestimate AstraZeneca’s intrinsic value and growth prospects.

AI Exposure / Tech Reliance

Operating in the healthcare sector, AstraZeneca is well-positioned to leverage AI for drug discovery and personalized medicine. The industry's shift towards data-driven solutions aligns with AstraZeneca's innovative approach. This adaptability ensures resilience in a rapidly evolving tech landscape.

The Bull Case

For the discerning GARP investor, AstraZeneca offers a tantalizing opportunity. The ROIC of 17.57% showcases exceptional capital efficiency, while a Piotroski F-Score of 8 signals strong financial health. With a Gross Profit Margin nearing 80%, the company demonstrates formidable pricing power. Despite a modest FCF Yield, its operational prowess and strategic investments promise long-term value creation.

The Bear Case

Yet, AstraZeneca is not without its flaws. The Price/Book ratio of 5.89 and Price/Sales of 4.59 suggest a premium valuation, potentially deterring deep value investors. The Current Ratio below 1 indicates liquidity concerns, raising questions about short-term financial flexibility. Additionally, trading near its 52-week high, the stock may be technically overextended, warranting caution.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$216.00

Institutional Ownership %

1-Year Beta

0.21

Insider Buying % (6 Mo)

Distance to 52-Week High

14.39%

Distance to 52-Week Low

26.21%

EARNINGS SURPRISE %

0.39%

50-DAY SMA

$190.41

200-DAY SMA

$181.29

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.